A new AI software developed by French start-up Volta Medical for helping cardiologists treat atrial fibrillation (AF) more effectively could be commercially available within two years. The Marseille-based company told Medtech Insight that it is currently in talks to secure some Series A funding to advance development of AIFib, take it through more clinical studies and hopefully launch it in 2020.
AF is caused by a dysfunction in the atria that disrupts the mechanical contraction of the heart. The irregular heartbeats prevent the heart from pumping blood efficiently which can cause...